Neurotrope: More than doubles on data from Alzheimer's drug study

NextTrip

22/01/2020 15:51

** Drug developer's shares  NTRP.O  more than double to
$3.10
    ** Neurotrope reports data from mid-stage confirmatory trial
examining Alzheimer's disease patients treated with co's main
drug Byrostatin-1 in the absence of memantine, another
Alzheimer's treatment  urn:newsml:reuters.com:*:nPn1C2LgTa
    ** NTRP says analysis of trial data showed significant
improvement in patients treated with Bryostatin-1 vs. those
given placebo
    ** Co also said it received $2.7 mln from the National
Institute of Health to support an additional mid-stage
confirmatory study
    ** NTRP plans to meet with the U.S. FDA to present clinical
program data for Bryostatin-1 from two trials
    ** Neurotrope continues to review multiple viable
alternatives, which were earlier announced in Oct. last year
 urn:newsml:reuters.com:*:nPn7MYgyqa
    ** More than 19.5 mln shares traded, ~93 times their 25-day
moving avg
    ** In 2019, stock fell ~72.5%
    

 (Reporting by Shivani Singh)
 ((ShivaniSingh1@thomsonreuters.com;))